文献速递糖尿病

低剂量磺脲类联合DPP4抑制剂降低血糖并增强β细胞功能且不引起低血糖

Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

在邓迪大学临床研究中心开展的非盲随机交叉研究,30例接受饮食或二甲双胍治疗的2型糖尿病参与者(HbA1c < 64 mmol/mol)完成4个14天干预阶段:对照、格列齐特20 mg、西格列汀100 mg及两药联合。联合治疗对降低血糖和改善β细胞葡萄糖敏感性均呈叠加效应,且连续血糖监测显示血糖低于3 mmol/L的时间比例未受影响。

要点

  • 低剂量磺脲类联合DPP4抑制剂对降低血糖和改善β细胞葡萄糖敏感性呈叠加效应。
  • 联合治疗组平均血糖曲线下面积最低,为8.7 mmol/L,优于单药及对照。
  • 连续血糖监测显示血糖低于3 mmol/L的时间比例在各组间无显著差异(P = .65)。

核心结论

  • 低剂量磺脲类联合DPP4抑制剂通过增强β细胞功能产生强效降糖作用,可能避免磺脲类的负面效应。
  • 作者认为需要一项双盲随机对照试验来正式确定该联合方案的疗效和安全性。

研究设计与样本

  • 非盲随机交叉研究,在邓迪大学临床研究中心开展。
  • 30例2型糖尿病参与者(HbA1c < 64 mmol/mol),接受饮食或二甲双胍治疗。
  • 参与者按随机顺序完成4个14天干预阶段:对照、格列齐特20 mg、西格列汀100 mg、联合治疗,每次干预后行混合餐试验。

主要发现

  • 平均血糖曲线下面积(均值95%CI,mmol/L):对照11.5(10.7-12.3),DPP4i 10.2(9.4-11.1),SU 9.7(8.9-10.5),SUDPP4i 8.7(7.9-9.5)(P < .001)。
  • 葡萄糖敏感性(pmol min-1 m-2 mM-1):对照71.5(51.1-91.9),DPP4i 75.9(55.7-96.0),SU 86.3(66.1-106.4),SUDPP4i 94.1(73.9-114.3)(P = .04)。
  • 叠加效应在男性中可见,女性中未见。
  • 连续血糖监测血糖低于3 mmol/L的时间比例(%):对照1(2-4),DPP4i 2(3-6),SU 1(0-4),SUDPP4i 3(2-7)(P = .65)。

局限性

  • 原文结论指出需要一项双盲随机对照试验来正式确定该联合方案的疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Low-dose sulfonylureas (SUs) have been found to augment the classical incretin effect, increase glucose sensitivity and late phase incretin potentiation. OBJECTIVE: To evaluate potential synergy between low-dose SU plus a dipeptidyl peptidase 4 (DPP4) inhibitor. METHODS: Unblinded randomized crossover study at the Clinical Research Centre, University of Dundee. Thirty participants with T2DM (HbA1c < 64 mmol/mol) were treated with diet or metformin. Participants completed 4, 14-day blocks in a random order: control, gliclazide 20 mg (SU), sitagliptin 100 mg (DPP4 inhibitor [DPP4i]), or combination (SUDPP4i). A mixed meal test was conducted after each intervention. The primary outcome was the effect of treatment on beta-cell glucose sensitivity. Secondary outcomes included frequency of glucose <3 mmol/L on continuous glucose monitoring, subanalyses by genotype (KNCJ11 E23K), gender, and body mass index. RESULTS: SU combination with DPP4i showed additive effect on glucose lowering: mean glucose area under the curve (mean 95% CI) (mmol/L) was control 11.5 (10.7-12.3), DPP4i 10.2 (9.4-11.1), SU 9.7 (8.9-10.5), SUDPP4i 8.7 (7.9-9.5) (P < .001). Glucose sensitivity mirrored the additive effect (pmol min-1 m-2 mM-1): control 71.5 (51.1-91.9), DPP4i 75.9 (55.7-96.0), SU 86.3 (66.1-106.4), SUDPP4i 94.1 (73.9-114.3) (P = .04). The additive effect was seen in men but not women. Glucose time in range <3 mmol/L on continuous glucose monitoring (%) was unaffected: control 1 (2-4), DPP4i 2 (3-6), SU 1 (0-4), SUDPP4i 3 (2-7) (P = .65). CONCLUSION: Low-dose sulfonylurea plus DPP4i has a potent glucose-lowering effect through augmentation of beta-cell function. A double-blind randomized controlled trial would formalize efficacy and safety of this combination, which may avoid negative aspects of SU.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cordiner RLM, Bedair K, Mari A, et al. Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia. J Clin Endocrinol Metab. 2024. PMID: 38267622. doi:10.1210/clinem/dgae033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。